{"id":"NCT00789750","sponsor":"Daiichi Sankyo","briefTitle":"Colesevelam as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus","officialTitle":"A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study of the Efficacy and Safety of WELCHOL as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus (T2DM)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-04","primaryCompletion":"2012-07","completion":"2012-07","firstPosted":"2008-11-13","resultsPosted":"2017-06-26","lastUpdate":"2017-06-26"},"enrollment":562,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Colesevelam","otherNames":["Welchol"]},{"type":"DRUG","name":"Placebo","otherNames":["No drug"]},{"type":"DRUG","name":"Pioglitazone","otherNames":["Actos"]}],"arms":[{"label":"Colesevelam","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The current study investigates colesevelam as add-on therapy to pioglitazone to improve glycemic control in subjects with type 2 diabetes mellitus not adequately controlled with pioglitazone monotherapy or pioglitazone in combination with either metformin or a sulfonylurea. The study will evaluate if colesevelam add-on to pioglitazone therapy for type 2 diabetes mellitus will be safe, well tolerated, and efficacious.","primaryOutcome":{"measure":"Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24","timeFrame":"Baseline, Week 24","effectByArm":[{"arm":"Colesevelam","deltaMin":-0.34,"sd":0.083},{"arm":"Placebo","deltaMin":-0.02,"sd":0.083}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":9},"locations":{"siteCount":141,"countries":["United States"]},"refs":{"pmids":["25054436"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":274},"commonTop":["Hypoglycaemia"]}}